As the Horizon acquisition reaps its benefits, Amgen is now turning eyes to its obesity and diabetes portfolio.

Discover why Amgen is a reliable wealth compounder with strong Q3 results, a promising pipeline, debt reduction, and ...

Wolfe Research analyst Alexandria Hammond initiated coverage of Amgen (AMGN) with a Peer Perform rating. With the antibody backbone, the firm ...

Sales for Lumakras and Blincyto in particular soared during the third quarter as the firm's overall revenues climbed 23 percent year over year.

Amgen's Immunology, Oncology, and Cardiology Portfolio Drives Its Wide Moat Amgen has its roots in providing supportive-care products to kidney disease and cancer patients, but the firm has ...

Amgen ( AMGN 1.68%), a leader in biotechnology, released its third-quarter 2024 financial results on Oct. 30. The company ...

The Chinese company also gets commercialisation rights to three already-marketed cancer drugs, as well as co-development rights to 20 candidates in its oncology pipeline, while Amgen gets to ...

The company now counts on an extensive portfolio of blockbuster drugs across fields like oncology ... Beyond the products ...

further strengthening Amgen's position in the oncology market. Enbrel, one of Amgen's established products, faces challenges in the Medicare Part D negotiations, with a 67% discount to list price.